tert-butyl [(1R,2R,3S)-4-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-1-(hydroxymethyl)-3-methylbutyl]carbamate | 1210418-63-5

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: tert-butyl [(1R,2R,3S)-4-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-1-(hydroxymethyl)-3-methylbutyl]carbamate
• 英文别名: tert-butyl (2R,3R,4S)-5-azido-3-(tert-butyldimethylsilyloxy)-1-hydroxy-4-methylpentan-2-ylcarbamate；tert-butyl N-[(2R,3R,4S)-5-azido-3-[tert-butyl(dimethyl)silyl]oxy-1-hydroxy-4-methylpentan-2-yl]carbamate
• CAS: 1210418-63-5
• 化学式: C₁₇H₃₆N₄O₄Si
• 分子量: 388.583
• InChiKey: HOFCDDHAWZFRSZ-BFHYXJOUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.21
• 重原子数：
  26
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  82.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tert-butyl [(1R,2R,3S)-4-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-1-(hydroxymethyl)-3-methylbutyl]carbamate 在 吡啶 、 4-二甲氨基吡啶 、 sodium azide 、 palladium 10% on activated carbon 、 四丁基氟化铵 、 氢气 、 铁粉 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 115.0 ℃ 、101.33 kPa 条件下， 反应 63.0h， 生成 di-tert-butyl {4-[(3R,4S,5S)-3-[(tert-butoxycarbonyl)amino]-5-methyl-4-(1H-1,2,3-triazol-1-yl)piperidin-1-yl]pyridin-3-yl}imidodicarbonate
  参考文献：
  名称：

  BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS

  摘要：

  本公开描述了双环芳香羧酰胺衍生物，以及它们的组成物和使用方法。这些化合物抑制Pim激酶的活性，并且在治疗与Pim激酶活性相关的疾病方面具有用处，例如癌症和其他疾病。

  公开号：

  US20140200216A1
• 作为产物：
  描述：

  在 二碳酸二叔丁酯 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 以605 mg的产率得到tert-butyl [(1R,2R,3S)-4-azido-2-{[tert-butyl(dimethyl)silyl]oxy}-1-(hydroxymethyl)-3-methylbutyl]carbamate
  参考文献：
  名称：

  Structure Guided Optimization, in Vitro Activity, and in Vivo Activity of Pan-PIM Kinase Inhibitors

  摘要：

  Proviral insertion of Moloney virus (PIM) 1, 2, and 3 kinases are serine/threonine kinases that normally function in survival and proliferation of hematopoietic cells. As high expression of PIM1, 2, and 3 is frequently observed in many human malignancies, including multiple myeloma, non Hodgkins lymphoma, and myeloid leukemias, there is interest in determining whether selective PIM1 inhibition can improve outcomes of these human cancers. Herein, we describe our efforts toward this goal. The structure guided optimization of a singleton high throughput screening hit in which the potency against all three PIM isoforms was increased >10,000 fold to yield compounds with pan PIM K(i)s < 10 pM, nanomolar cellular potency, and in vivo activity in an acute myeloid leukemia Pun dependent tumor model is described.

  DOI：

  10.1021/ml400307j

文献信息

• [EN] PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRIDINEAMINE UTILES EN TANT QU'INHIBITEURS DE KINASE PIM
  申请人：INCYTE CORP

  公开号：WO2016196244A1

  公开（公告）日：2016-12-08

  The present disclosure describes pyridineamine compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer, immune disorders and other diseases. Formula (I).

  本公开描述了吡啶胺化合物，以及它们的组成和使用方法。这些化合物抑制Pim激酶的活性，并且在治疗与Pim激酶活性相关的疾病方面具有用途，例如癌症、免疫紊乱和其他疾病。公式（I）。
• FURO- AND THIENO-PYRIDINE CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
  申请人：Incyte Corporation

  公开号：US20150057265A1

  公开（公告）日：2015-02-26

  The present disclosure describes furo- and thieno-pyridine carboxamide compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

  本公开描述了呋喃和噻吩吡啶羧酰胺化合物，以及它们的组合物和使用方法。这些化合物抑制Pim激酶的活性，并且在治疗与Pim激酶活性相关的疾病方面具有用处，例如癌症和其他疾病。
• Kinase inhibitors and methods of their use
  申请人：BURGER Matthew T.

  公开号：US20100056576A1

  公开（公告）日：2010-03-04

  New compounds, compositions and methods of inhibition of Provirus Integration of Maloney Kinase (PIM kinase) activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one PIM kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.

  提供了一种新的化合物、组合物和抑制与人类或动物宿主肿瘤发生相关的莫洛尼激酶（PIM激酶）活性的方法。在某些实施例中，该化合物和组合物能有效抑制至少一种PIM激酶的活性。这些新的化合物和组合物可以单独使用，也可以与至少一种其他试剂联合使用，用于治疗由丝氨酸/苏氨酸激酶或受体酪氨酸激酶介导的疾病，如癌症。
• [EN] NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS<br/>[FR] NOUVEAUX N-PYRIDINYLAMIDES SUBSTITUÉS PAR UN CYCLE À TITRE D'INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2013175388A1

  公开（公告）日：2013-11-28

  The present invention provides a compound of formula (A): I as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.

  本发明提供了一种公式的化合物(A): I，如本文所述，以及药用可接受的盐、对映体、旋转异构体、互变异构体或外消旋混合物。还提供了使用公式I的化合物治疗由PIM激酶介导的疾病或状况的方法，以及包含这些化合物的药物组合物。
• THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
  申请人：Incyte Corporation

  公开号：US20140200227A1

  公开（公告）日：2014-07-17

  The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

  本公开描述了噻唑和吡啶羧酰胺衍生物，它们的组成以及使用方法。这些化合物抑制Pim激酶的活性，并且在治疗与Pim激酶活性相关的疾病方面具有用途，例如癌症和其他疾病。